Cactus Life Sciences Top 5 Trends of 2024

Cactus Life Sciences’ Top 5 Trends of 2024: Insights Driving Tomorrow’s MedComms

Here, we revisit our most thought-provoking articles and whitepapers, each addressing pivotal trends that influence the ever-evolving biopharma landscape...
Read More

Top Stories

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Involve Medical Affairs in insight management, early phases of clinical trials, etc.

It’s Never Too Soon: How and When to

Engagement with Medical Affairs is critical at every...
Leverage Social Media to Transform Medical Affairs | Promoting Disease Awareness, Ensuring Compliance and Assessing Outcomes

Leveraging Social Media to Transform Medical

This whitepaper explores the role of social media in...
FINAL Clinical Trial Summaries Blog-Banner-810x540

Clinical Trial Summaries – What Are They and Why Do They Matter for Pharma?

A majority of patients feel lay summaries for clinical trials are very important and won’t...
equity diversity and inclusion

How to Incorporate and Drive Equity, Diversity, and Inclusion in Medical Communications and Publications

A roadmap on how to drive advocacy for EDI in medical communications and publications and...
Building public trust in pharma

3 Factors That Will Help Pharma Build Public Trust

Pharma must engage with patients at all levels to build public trust...
Image for the graphical abstracts blog by Cactus Life Sciences

Reel Your Audience in with a Visual Abstract

Graphical abstracts allow room for science communication to be reimagined in a range of creative...
Vaccine

Role of Scientific Communication and Medical Professionals in Combating Vaccine Hesitancy

Read an insightful discussion from the latest ISMPP conference on how science communication and medical...
UX design for scientific writing

Future of Scientific Writing and Journal Articles with UX Design

Take a look at some ideas and examples on how user experience design can be...

Learn more ABOUT our company.